Loading...

Diane Marie Da Silva, PhD, MS

Title(s)Assistant Professor of Research Obstetrics & Gynecology
AddressNRT 7517
Health Sciences Campus
Los Angeles CA 90089-9601
Phone+1 323 442 3868
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Dr. Da Silva's current research interests span multiple areas of study that include applying immune modulation strategies to enhance natural and vaccine-induced immunity against solid tumors, investigating the molecular and cellular determinants in the tumor microenvironment that lead to cancer development, progression and metastasis, and assessing the clinical significance of the cervico-vaginal microbiota in relation to gynecologic cancer development, progression and response to treatment.

    Dr. Da Silva has broad expertise and skills associated with immunology, oncology and infectious disease research, immunotherapeutics, vaccine immunogenicity and efficacy, pre-clinical vaccine/adjuvant development, small animal syngeneic and xenograft tumor models, clinical translational research, and analysis of immune responses and biomarkers in human clinical samples for many different types of cancer. Dr. Da Silva is the Technical Director of the Norris Comprehensive Cancer Center Beckman Center for Immune Monitoring, a core resource for collecting, processing and analyzing human clinical trial samples to discover and validate immune-related biomarkers of response to cancer therapies. She has spent the past 15 years studying human papillomavirus (HPV) interactions with host immune cell receptors and immune escape mechanisms used by HPV, and has been involved with development of therapeutic vaccine strategies against HPV-induced cancers.

    Since 2015, Dr. Da Silva is the course director for the undergraduate Introductory course in Modern Oncology and Cancer Biology for the USC Minor in Health Care Studies.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Theta-Defensins Inhibit High-Risk Human Papillomavirus Infection Through Charge-Driven Capsid Clustering. Front Immunol. 2020; 11:561843. Skeate JG, Segerink WH, Garcia MD, Fernandez DJ, Prins R, Lühen KP, Voss FO, Da Silva DM, Kast WM. PMID: 33154746.
      View in: PubMed   Mentions:    Fields:    
    2. Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929). Clin Cancer Res. 2020 Nov 01; 26(21):5621-5630. Da Silva DM, Enserro DM, Mayadev JS, Skeate JG, Matsuo K, Pham HQ, Lankes HA, Moxley KM, Ghamande SA, Lin YG, Schilder RJ, Birrer MJ, Kast WM. PMID: 32816895.
      View in: PubMed   Mentions:    Fields:    
    3. TNFSF14: LIGHTing the Way for Effective Cancer Immunotherapy. Front Immunol. 2020; 11:922. Skeate JG, Otsmaa ME, Prins R, Fernandez DJ, Da Silva DM, Kast WM. PMID: 32499782.
      View in: PubMed   Mentions:    Fields:    
    4. Vaccination against Nonmutated Neoantigens Induced in Recurrent and Future Tumors. Cancer Immunol Res. 2020 07; 8(7):856-868. Garrido G, Schrand B, Levay A, Rabasa A, Ferrantella A, Da Silva DM, D'Eramo F, Marijt KA, Zhang Z, Kwon D, Kortylewski M, Kast WM, Dudeja V, van Hall T, Gilboa E. PMID: 32295785.
      View in: PubMed   Mentions: 1     Fields:    
    5. The Essential Role of anxA2 in Langerhans Cell Birbeck Granules Formation. Cells. 2020 04 15; 9(4). Thornton SM, Samararatne VD, Skeate JG, Buser C, Lühen KP, Taylor JR, Da Silva DM, Kast WM. PMID: 32326440.
      View in: PubMed   Mentions: 1     Fields:    
    6. Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer. JAMA Oncol. 2019 Nov 27. Mayadev JS, Enserro D, Lin YG, Da Silva DM, Lankes HA, Aghajanian C, Ghamande S, Moore KN, Kennedy VA, Fracasso PM, Schilder RJ. PMID: 31774464.
      View in: PubMed   Mentions: 5     Fields:    
    7. Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease. Vaccine. 2019 05 16; 37(22):2915-2924. Da Silva DM, Skeate JG, Chavez-Juan E, Lühen KP, Wu JM, Wu CM, Kast WM, Hwang K. PMID: 31010714.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    8. Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study. BMC Cancer. 2018 Oct 11; 18(1):970. Brunette LL, Mhawech-Fauceglia PY, Ji L, Skeate JG, Brand HE, Lawrenson K, Walia S, Chiriva-Internati M, Groshen S, Roman LD, Kast WM, Da Silva DM. PMID: 30309325.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    9. Cervico-vaginal self-collection in HIV-infected and uninfected women from Tapajós region, Amazon, Brazil: High acceptability, hrHPV diversity and risk factors. Gynecol Oncol. 2018 10; 151(1):102-110. Rodrigues LLS, Morgado MG, Sahasrabuddhe VV, De Paula VS, Oliveira NS, Chavez-Juan E, Da Silva DM, Kast WM, Nicol AF, Pilotto JH. PMID: 30087059.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsPHPublic Health
    10. Heterotetrameric annexin A2/S100A10 (A2t) is essential for oncogenic human papillomavirus trafficking and capsid disassembly, and protects virions from lysosomal degradation. Sci Rep. 2018 08 03; 8(1):11642. Taylor JR, Fernandez DJ, Thornton SM, Skeate JG, Lühen KP, Da Silva DM, Langen R, Kast WM. PMID: 30076379.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    11. Nanobody-Antigen Conjugates Elicit HPV-Specific Antitumor Immune Responses. Cancer Immunol Res. 2018 07; 6(7):870-880. Woodham AW, Cheloha RW, Ling J, Rashidian M, Kolifrath SC, Mesyngier M, Duarte JN, Bader JM, Skeate JG, Da Silva DM, Kast WM, Ploegh HL. PMID: 29792298.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCellsPHPublic Health
    12. Nano-Pulse Stimulation induces immunogenic cell death in human papillomavirus-transformed tumors and initiates an adaptive immune response. PLoS One. 2018; 13(1):e0191311. Skeate JG, Da Silva DM, Chavez-Juan E, Anand S, Nuccitelli R, Kast WM. PMID: 29324830.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    13. T cell ignorance is bliss: T cells are not tolerized by Langerhans cells presenting human papillomavirus antigens in the absence of costimulation. Papillomavirus Res. 2016 12; 2:21-30. PMID: 27182559.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    14. Annexin A2 antibodies but not inhibitors of the annexin A2 heterotetramer impair productive HIV-1 infection of macrophages in vitro. Virol J. 2016 11 18; 13(1):187. PMID: 27863502.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    15. Secretory Leukocyte Protease Inhibitor Expression and High-Risk HPV Infection in Anal Lesions of HIV-Positive Patients. . 2016 09 01; 73(1):27-33. PMID: 27149102.
      View in: PubMed   Mentions:
    16. Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment. AIDS Patient Care STDS. 2016 07; 30(7):291-306. PMID: 27410493.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    17. Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. Hum Vaccin Immunother. 2016 06 02; 12(6):1418-29. PMID: 26835746.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    18. Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells. J Interferon Cytokine Res. 2016 05; 36(5):291-301. PMID: 26653678.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    19. Human papillomavirus-exposed Langerhans cells are activated by stabilized Poly-I:C. Papillomavirus Res. 2015 Dec 01; 1:12-21. PMID: 26665182.
      View in: PubMed   Mentions: 6     Fields:    
    20. Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection. J Gen Virol. 2016 Feb; 97(2):422-434. PMID: 26555393.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    21. Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C. Clin Immunol. 2015 Dec; 161(2):197-208. PMID: 26360252.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    22. A novel murine model for evaluating bovine papillomavirus prophylactics/therapeutics for equine sarcoid-like tumours. J Gen Virol. 2015 Sep; 96(9):2764-2768. PMID: 26044793.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    23. Small molecule inhibitors of the annexin A2 heterotetramer prevent human papillomavirus type 16 infection. J Antimicrob Chemother. 2015; 70(6):1686-90. PMID: 25712315.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    24. Functional analysis of HPV-like particle-activated Langerhans cells in vitro. Methods Mol Biol. 2015; 1249:333-50. PMID: 25348318.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsPHPublic Health
    25. Molecular analysis of human papillomavirus virus-like particle activated Langerhans cells in vitro. Methods Mol Biol. 2015; 1249:135-49. PMID: 25348303.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    26. Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes. Prostate. 2015 Feb 15; 75(3):280-91. PMID: 25399517.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    27. Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression. J Immunol. 2014 May 15; 192(10):4748-57. PMID: 24719459.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCellsCTClinical Trials
    28. Suppression of Langerhans cell activation is conserved amongst human papillomavirus a and ß genotypes, but not a µ genotype. Virology. 2014 Mar; 452-453:279-86. PMID: 24606705.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    29. The evolving field of human papillomavirus receptor research: a review of binding and entry. J Virol. 2013 Jun; 87(11):6062-72. PMID: 23536685.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansAnimalsCells
    30. The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PLoS One. 2012; 7(8):e43519. PMID: 22927980.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCells
    31. Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression. Cancer Res. 2010 May 15; 70(10):3955-64. Kanodia S, Da Silva DM, Karamanukyan T, Bogaert L, Fu YX, Kast WM. PMID: 20460520.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    32. Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer. 2010 Jan 15; 116(2):424-31. Clark JI, Moon J, Hutchins LF, Sosman JA, Kast WM, Da Silva DM, Liu PY, Thompson JA, Flaherty LE, Sondak VK. PMID: 19918923.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    33. A major role for the minor capsid protein of human papillomavirus type 16 in immune escape. J Immunol. 2009 Nov 15; 183(10):6151-6. Fahey LM, Raff AB, Da Silva DM, Kast WM. PMID: 19864613.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    34. Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors. Clin Cancer Res. 2009 Oct 01; 15(19):6167-76. Smith KA, Meisenburg BL, Tam VL, Pagarigan RR, Wong R, Joea DK, Lantzy L, Carrillo MA, Gross TM, Malyankar UM, Chiang CS, Da Silva DM, Kündig TM, Kast WM, Qiu Z, Bot A. PMID: 19789304.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    35. Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16. J Immunol. 2009 Mar 01; 182(5):2919-28. Fahey LM, Raff AB, Da Silva DM, Kast WM. PMID: 19234187.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    36. Sperm fibrous sheath proteins: a potential new class of target antigens for use in human therapeutic cancer vaccines. Cancer Immun. 2008 Apr 24; 8:8. Chiriva-Internati M, Cobos E, Da Silva DM, Kast WM. PMID: 18433090.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    37. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer. 2008 Jan 15; 122(2):247-59. Kanodia S, Da Silva DM, Kast WM. PMID: 17973257.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    38. Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity. J Immunol. 2007 Jun 15; 178(12):7587-97. Da Silva DM, Fausch SC, Verbeek JS, Kast WM. PMID: 17548594.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    39. Human papillomavirus L1L2-E7 virus-like particles partially mature human dendritic cells and elicit E7-specific T-helper responses from patients with cervical intraepithelial neoplasia or cervical cancer in vitro. Hum Immunol. 2005 Jul; 66(7):762-72. Warrino DE, Olson WC, Scarrow MI, D'Ambrosio-Brennan LJ, Guido RS, Da Silva DM, Kast WM, Storkus WJ. PMID: 16112023.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    40. Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation. J Immunol. 2005 Jun 01; 174(11):7172-8. Fausch SC, Fahey LM, Da Silva DM, Kast WM. PMID: 15905561.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    41. Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells. Vaccine. 2005 Feb 25; 23(14):1720-9. Fausch SC, Da Silva DM, Kast WM. PMID: 15705478.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    42. Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine. 2003 Jul 04; 21(23):3219-27. Da Silva DM, Schiller JT, Kast WM. PMID: 12804851.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    43. Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res. 2003 Jul 01; 63(13):3478-82. Fausch SC, Da Silva DM, Kast WM. PMID: 12839929.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    44. Cervical cancer vaccines: recent advances in HPV research. Viral Immunol. 2003; 16(2):111-21. Eiben GL, da Silva DM, Fausch SC, Le Poole IC, Nishimura MI, Kast WM. PMID: 12828864.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    45. HPV protein/peptide vaccines: from animal models to clinical trials. Front Biosci. 2003 Jan 01; 8:s81-91. Fausch SC, Da Silva DM, Eiben GL, Le Poole IC, Kast WM. PMID: 12456298.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    46. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol. 2002 Sep 15; 169(6):3242-9. Fausch SC, Da Silva DM, Rudolf MP, Kast WM. PMID: 12218143.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimalsCells
    47. Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention. Intervirology. 2002; 45(4-6):300-7. Wakabayashi MT, Da Silva DM, Potkul RK, Kast WM. PMID: 12566713.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    48. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines. Virology. 2001 Nov 25; 290(2):350-60. Da Silva DM, Pastrana DV, Schiller JT, Kast WM. PMID: 11883199.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    49. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J Immunol. 2001 May 15; 166(10):5917-24. Rudolf MP, Fausch SC, Da Silva DM, Kast WM. PMID: 11342606.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCells
    50. Physical interaction of human papillomavirus virus-like particles with immune cells. Int Immunol. 2001 May; 13(5):633-41. Da Silva DM, Velders MP, Nieland JD, Schiller JT, Nickoloff BJ, Kast WM. PMID: 11312251.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    51. A murine model for the effects of pelvic radiation and cisplatin chemotherapy on human papillomavirus vaccine efficacy. Clin Cancer Res. 2001 Mar; 7(3 Suppl):876s-881s. Small LA, Da Silva DM, de Visser KE, Velders MP, Fisher SG, Potkul RK, Kast WM. PMID: 11300486.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    52. Cervical cancer vaccines: emerging concepts and developments. J Cell Physiol. 2001 Feb; 186(2):169-82. Da Silva DM, Eiben GL, Fausch SC, Wakabayashi MT, Rudolf MP, Velders MP, Kast WM. PMID: 11169454.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    53. Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response. J Cell Biochem. 1999 May 01; 73(2):145-52. Nieland JD, Da Silva DM, Velders MP, de Visser KE, Schiller JT, Müller M, Kast WM. PMID: 10227378.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    54. Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles. Biol Chem. 1999 Mar; 380(3):335-40. Rudolf MP, Nieland JD, DaSilva DM, Velders MP, Müller M, Greenstone HL, Schiller JT, Kast WM. PMID: 10223336.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    55. Papillomavirus virus-like particles as anticancer vaccines. Curr Opin Mol Ther. 1999 Feb; 1(1):82-8. Da Silva DM, Velders MP, Rudolf MP, Schiller JT, Kast WM. PMID: 11249689.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    56. Cellular immunity and immunotherapy against deoxyribonucleic acid virus-induced tumors. Monaldi Arch Chest Dis. 1998 Apr; 53(2):211-8. Macedo MF, Velders MP, Nieland JD, Rudolf MP, Weijzen S, Da Silva DM, Franke A, Holt G, Loviscek K, Carbone M, Kast WM. PMID: 9689811.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    Diane's Networks
    Concepts (262)
    Derived automatically from this person's publications.
    _
    Co-Authors (14)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _